An observational study in Social Care, Medical Care and Elderly Patients, sponsored by Gérond'if. Recruiting at 10 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Gérond'if · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Prospective, observational, non-interventional, comparative, multicenter RIPH3 study to investigate the impact of HTSH on length of hospital stay in referring services.
This is a multi-center study involving many hospital departments temporary accommodation at the end of hospitalization in several Nursing home/long term care units in Ile de France region. The temporary accommodation program was designed for elderly people living at home to find an accommodation solution in nursing home to meet a short-term need. Temporary accommodation beds are deployed and perpetuated in the Île-de-France region by the Regional Health Agency, physically grouped together in establishments within units with dedicated staff. The resources allocated to these beds have been increased. The aim of the study is to demonstrate the efficiency of the HTSH circuit, for elderly patients leaving hospital, in their medical and social care and the decision or not to return home. This project is supported by Regional Health Agency (ARS-IDF).
Gérond'if is the lead sponsor of 35 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
258 subjects in the prospective group. Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.
Inclusion Criteria:
Patient selection criteria
Caregiver selection criteria
Professional selection criteria
Non-inclusion Criteria:
258 subjects in the prospective group
Retrospective data will be collected directly from hospital departments by ARS IDF or from physicians responsible for medical information (RMI) within each hospital center participating in the study, for the 2 years 2021 and 2022 prior to the study and compared with the average length of stay for services to be calculated at the end of the study.
Study to investigate the impact of HTSH on length of hospital stay in referring services
The main assessment criterion is based on the average length of stay observed at the end of the study, compared with that of the previous two years, 2021 and 2022, in the referring services.
Time frame: 24 months
Analysis of pathways and plans for returning home
Evaluation criteria: Calculation of the proportion of patients in the life project on admission to nursing home / long term care units and the return home at the end of the stay.
Time frame: 24 months
Analysis of HTSH patient profiles a) Proportion of eligible patients and their comorbidities b) Social profile + main reason for hospitalization of patients admitted to HTSH
Evaluation criteria: Ratio of hospital ward activity data to pre-screening data collected during the study.
Time frame: 24 months
Analysis of discharges and patient outcomes
Proportion of patients remaining at home in the medium term Patients' functional outcome after the trial
Time frame: 24 months
Quality of life and caregiver benefit analysis
Quality of life assessment
Time frame: 24 months
Not enrolling at this site.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gérond'if